Traynor Capital Management Inc. reduced its position in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 3.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,267 shares of the biopharmaceutical company stock after selling 433 shares during the period. Traynor Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $ 822,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of BMY. Steward Financial Group LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $ 29,000. Horan Securities Inc. bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $ 29,000. Guardian Wealth Management Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $ 32,000. Consolidated Planning Corp bought a new position in shares of Bristol-Myers Squibb during the third quarter worth approximately $ 34,000. Finally, Leverty Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $ 37,000. 73.07% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently weighed in on BMY shares. Bank of America upped their price objective on shares of Bristol-Myers Squibb from $ 78.00 to $ 80.00 and gave the stock a “buy” rating in a research report on Monday, June 6th. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $ 76.00 to $ 81.00 in a research report on Monday, May 2nd. Barclays boosted their price target on shares of Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a research report on Monday, May 2nd. StockNews.com began coverage on Bristol-Myers Squibb in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Finally, Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $ 65.00 to $ 70.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $ 74.27.
In related news, EVP Sandra Leung sold 65,000 shares of the company stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the sale, the executive vice president now directly owns 308,627 shares in the company, valued at $ 23,113,076.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Giovanni Caforio sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $ 74.04, for a total transaction of $ 2,221,200.00. Following the transaction, the chief executive officer now owns 551,104 shares of the company stock, valued at approximately $ 40,803,740.16. The disclosure for this sale can be found here. Insiders own 0.09% of the company stock.
NYSE: BMY opened at $ 76.55 on Thursday. The stock’s 50-day moving average is $ 75.93 and its 200-day moving average is $ 69.82. Bristol-Myers Squibb has a 1-year low of $ 53.22 and a 1-year high of $ 78.61. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 1.18. The stock has a market cap of $ 162.98 billion, a P / E ratio of 27.15, a price-to-earnings-growth ratio of 1.62 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last posted its earnings results on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $ 1.92 by $ 0.04. The firm had revenue of $ 11.65 billion for the quarter, compared to analyst estimates of $ 11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $ 1.74 EPS. As a group, equities analysts forecast that Bristol-Myers Squibb will post 7.56 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be issued a dividend of $ 0.54 per share. This represents a $ 2.16 annualized dividend and a yield of 2.82%. The ex-dividend date is Thursday, June 30th. Bristol-Myers Squibb’s payout ratio is presently 76.60%.
About Bristol-Myers Squibb: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.